Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL

Enrollment

374

Participants

Timeline

Start Date

April 12, 2016

Primary Completion Date

April 20, 2018

Study Completion Date

September 20, 2018

Conditions

Primary Hypercholesterolemia

Interventions

DRUG

HS-25

HS-25 10mg/tablet, 20mg,once daily,for 12 weeks, and then HS-25 20mg once daily for 40 weeks.

DRUG

Placebo of HS-25

Placebo HS-25 10mg/tablet, 20mg,once daily,for 12 weeks,and then HS-25 20mg once daily for 40 weeks.

All Listed Sponsors

lead

Zhejiang Hisun Pharmaceutical Co. Ltd.

INDUSTRY

NCT03413462 - Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia | Biotech Hunter | Biotech Hunter